Around one-third of patients with peripheral arterial disease (PAD) fail to receive appropriate antiplatelet treatment, warns a review from an expert panel, which highlights the huge cost of sub-optimal treatment of PAD on the NHS, the economy as a whole and on the individuals affected.
